Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Joselyn Del Rosario"'
Autor:
Chandtip Chandhasin, Van Dang, Frank Perabo, Joselyn Del Rosario, Young K. Chen, Ellen Filvaroff, Jeffrey A. Stafford, Michael Clarke
Publikováno v:
Anti-Cancer Drugs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e5552b54142cf337f82a98968d134cf
https://doi.org/10.1097/cad.0000000000001514
https://doi.org/10.1097/cad.0000000000001514
Autor:
Frank Perabo, Chandtip Chandhasin, Sanghee Yoo, Joselyn Del Rosario, Young K. Chen, Ellen Filvaroff, Jeffrey A. Stafford, Stephen Quake, Michael F. Clarke
Publikováno v:
Cancer Research. 82:3720-3720
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the US accounting for about 22% of newly diagnosed cases of B-cell NHL. It is considered to be more aggressive and to have worse prognosis due
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12bfd88a7f3549390881a226e2b51ade
https://doi.org/10.1158/1538-7445.am2022-3720
https://doi.org/10.1158/1538-7445.am2022-3720
Autor:
Frank Perabo, Chandtip Chandhasin, Van Dang, Joselyn Del Rosario, Young K Chen, Ellen Filvaroff, Jeffrey Stafford, Stephen Quake, Michael F. Clarke
Publikováno v:
Journal of Clinical Oncology. 40:e15105-e15105
e15105 Background: Cancer stem cells (CSCs) are believed to be responsible for both therapy resistance and metastasis. Until now, these resistant CSCs have not been well-characterized, and potential treatments targeting these cells have yet to be ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cac55a1a2d430f9219423146c1b45c46
https://doi.org/10.1200/jco.2022.40.16_suppl.e15105
https://doi.org/10.1200/jco.2022.40.16_suppl.e15105
Publikováno v:
Universidad Peruana de Ciencias Aplicadas (UPC)Repositorio Académico - UPC.
En el presente trabajo de investigación se muestra la relación que existe entre la disminución de la pobreza, el crecimiento económico de un país y el aporte de las MYPE, basados en conceptos de especialistas. Además, se desarrolla una investig
Externí odkaz:
http://hdl.handle.net/10757/655232
Autor:
Frank Perabo, Chandtip Chandhasin, Sanghee Yoo, Van Dang, Joselyn Del Rosario, Young K Chen, Jeffrey Stafford, Stephen Quake, Michael F. Clarke
Publikováno v:
Journal of Clinical Oncology. 40:132-132
132 Background: TACH101 is a novel, potent small molecule inhibitor of KDM4, a novel epigenetic target for cancer therapy. KDM4 is a family of histone lysine demethylases that, when overexpressed, drives key processes linked to cancer. Validation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a35338412146ed029272fe5f71ba7bb4
https://doi.org/10.1200/jco.2022.40.4_suppl.132
https://doi.org/10.1200/jco.2022.40.4_suppl.132
Autor:
Frank Perabo, Sanghee Yoo, Chandtip Chandhasin, Joselyn Del Rosario, Young K. Chen, Ellen Filvaroff, Jeffrey A. Stafford, Stephen Quake, Michael F. Clarke
Publikováno v:
Molecular Cancer Therapeutics. 20:P086-P086
Background: TACH101 is a novel, selective and potent inhibitor of KDM4 in development for advanced cancers. KDM4 plays a key role in epigenetic regulation by removing methyl marks on histone H3K9 and H3K36. Overexpression of KDM4 leads to dysregulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1921687f05e9c24ce9ea82192e193fcb
https://doi.org/10.1158/1535-7163.targ-21-p086
https://doi.org/10.1158/1535-7163.targ-21-p086
Autor:
Joselyn Del Rosario, Michelle Parish, Bin Liu, Jie Huang, Ping Jin, Dingguo Liu, Marla J. Matin, Gary Woodnutt, Bryan Oates, Jing-Yu Lai, Nancy Levin, Rodney W. Lappe, Curt W. Bradshaw, Richard A. Lerner, Crystal Hagen, Abhijit Bhat, Robert E. Murphy, Zemeda W Ainekulu, Michael J. Shields, Venkata Doppalapudi, Lingna Li, Joel Desharnais
Publikováno v:
Proceedings of the National Academy of Sciences. 107:22611-22616
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3aab9d8b9d6a1442038b30b585337d7
https://doi.org/10.1073/pnas.1016478108
https://doi.org/10.1073/pnas.1016478108
Autor:
Mark Horn, Ruth Muchekehu, Joselyn Del Rosario, Steven Pirie-Shepherd, Allan Kaspar, Dingguo Liu, Venkata Doppalapudi, Trina Osothprarop, Julia Coronella, Haim Moskowitz, Michael Bacica, Lioudmila Campbell, Anouk Dirksen
Publikováno v:
Translational oncology. 6(5)
Poor drug delivery and penetration of antibody-mediated therapies pose significant obstacles to effective treatment of solid tumors. This study explored the role of pharmacokinetics, valency, and molecular weight in maximizing drug delivery. Biodistr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34af362ceb89442cdb636bf9acb59cdc
https://pubmed.ncbi.nlm.nih.gov/24151537
https://pubmed.ncbi.nlm.nih.gov/24151537
Autor:
Kristen E Bower, Ryan Preston, Emily Corner, Robert E. Murphy, Arvind G. Kinhikar, Xia Cao, Zemeda W Ainekulu, Aakash B Datt, Steven Pirie-Shepherd, Lioudmila Campbell, Gang Chen, Venkata Doppalapudi, Joselyn Del Rosario, Hanhua Huang, Bryan Oates, Rodney W. Lappe, Son Lam, Trina Osothprarop, Nancy Levin, Curt Bradshaw, Gary Woodnutt, Julie A Hoye, Judith Jimenez
Publikováno v:
Journal of medicinal chemistry. 54(5)
Novel phage-derived peptides are the first reported molecules specifically targeting human placental growth factor 1 (PlGF-1). Phage data enabled peptide modifications that decreased IC(50) values in PlGF-1/VEGFR-1 competition ELISA from 100 to 1 μM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d778774e40714032c80844e89f7bc95
https://pubmed.ncbi.nlm.nih.gov/21280651
https://pubmed.ncbi.nlm.nih.gov/21280651
Autor:
Gary H. Ward, Robert E. Murphy, Arvind G. Kinhikar, Joselyn Del Rosario, Ryan Preston, Nancy Levin, Michael J. Shields
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 53(3)
Peptides and monoclonal antibodies have both emerged as important therapeutic modalities, but each has challenges which limit their use. Non-recombinant chemical conjugation of peptides onto antibodies has the potential to minimize or eliminate altog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f6cf05215036c115f0d62b6d581efb2
https://pubmed.ncbi.nlm.nih.gov/20547023
https://pubmed.ncbi.nlm.nih.gov/20547023